ATE364048T1 - Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität - Google Patents

Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Info

Publication number
ATE364048T1
ATE364048T1 AT04011673T AT04011673T ATE364048T1 AT E364048 T1 ATE364048 T1 AT E364048T1 AT 04011673 T AT04011673 T AT 04011673T AT 04011673 T AT04011673 T AT 04011673T AT E364048 T1 ATE364048 T1 AT E364048T1
Authority
AT
Austria
Prior art keywords
cea
peptides
carcinoembryonic antigen
antagonistic activity
tachykinin antagonistic
Prior art date
Application number
AT04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE364048T1 publication Critical patent/ATE364048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04011673T 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität ATE364048T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE364048T1 true ATE364048T1 (de) 2007-06-15

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE267213T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69837896T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2217585T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010379A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
DE69941703D1 (de) * 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2003059379A2 (en) * 2002-01-17 2003-07-24 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
KR101455222B1 (ko) * 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
EP2170384B1 (de) 2007-07-02 2016-04-13 Etubics Corporation Verfahren und zusammensetzungen zur herstellung eines adenovirus-vektors zur verwendung mit multiplen impfungen
CA2817054C (en) 2007-07-27 2017-02-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2795833T3 (es) 2015-01-09 2020-11-24 Etubics Corp Composiciones para la vacunación contra el virus del Ebola
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
EP3286213B1 (de) 2015-04-20 2021-08-04 Etubics Corporation Verfahren und zusammensetzungen für eine kombinationsimmuntherapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584266B1 (de) * 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
ES2217585T3 (es) 2004-11-01
DE69824023D1 (de) 2004-06-24
PT1447414E (pt) 2007-07-18
AU745863B2 (en) 2002-04-11
CA2308127C (en) 2011-03-22
CY1107706T1 (el) 2013-04-18
WO1999019478A1 (en) 1999-04-22
CA2308127A1 (en) 1999-04-22
DE69837896T2 (de) 2008-02-14
AU9500498A (en) 1999-05-03
DE69824023T2 (de) 2005-05-12
JP4291508B2 (ja) 2009-07-08
ATE267213T1 (de) 2004-06-15
EP1017810A1 (de) 2000-07-12
EP1017810B1 (de) 2004-05-19
DE69837896D1 (de) 2007-07-19
DK1447414T3 (da) 2007-09-10
JP2002500002A (ja) 2002-01-08
ES2286530T3 (es) 2007-12-01

Similar Documents

Publication Publication Date Title
ATE364048T1 (de) Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
PT935607E (pt) Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
EA199800946A1 (ru) Концентрированный препарат антител
TR200003843T2 (tr) HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
DK0662000T3 (da) Antigen-bærende mikropartikler og deres anvendelse til at inducere humorale eller cellulære responser
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
ATE68960T1 (de) Shampoo-praeparate.
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
ATE458494T1 (de) Von der telomerase abgeleitete antigene peptide
ES2174837T3 (es) Conjugados de saponina-antigeno y su utilizacion.
ATE296348T1 (de) Cytokin lerk-7
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DE69922822D1 (de) Rekombinante haarbehandlungsmittel
BG102362A (en) New derivatives of amino acids, their preparation and application
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
HU9300900D0 (en) Human gamma-interferon antagonists
ATE174625T1 (de) Rekombinante hybride porinepitope
DE69637078D1 (de) Polypeptid-fragmente die fähig sind mit dem antigen i/ii von streptococcus mutans zu konkurrieren
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
SE8502540L (sv) Stabilt tandvardsmedel innehallande dextranas
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
ES2005753A6 (es) Procedimiento para la preparacion de polipeptidos inmunologicamente activos utiles para la obtencion de vacunas antimalaria y para la deteccion de enfermedades paludicas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1447414

Country of ref document: EP